Extracellular Vesicle-Mediated Synuclein Propagation Hypothesis in Parkinson's Disease

Migration, Crosslink

📖

Extracellular Vesicle-Mediated Synuclein Propagation Hypothesis in Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:33 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-hypotheses-extracellular-vesicle-sy

📖 Wiki Page

hypothesis2963 wordssynced 2026-04-02

Overview

The Extracellular Vesicle (EV)-Mediated Synuclein Propagation Hypothesis proposes that alpha-synuclein pathology spreads between neurons and from the peripheral nervous system to the central nervous system via extracellular vesicles—including exosomes (30-150 nm) and microvesicles (100-1000 nm). This mechanism provides a protective compartment for synuclein species, potentially explaining both the progressive nature of Parkinson's disease and the detectability of pathological markers in peripheral biofluids.

Mechanistic Framework

1. EV Biogenesis in Affected Neurons

...

Overview

The Extracellular Vesicle (EV)-Mediated Synuclein Propagation Hypothesis proposes that alpha-synuclein pathology spreads between neurons and from the peripheral nervous system to the central nervous system via extracellular vesicles—including exosomes (30-150 nm) and microvesicles (100-1000 nm). This mechanism provides a protective compartment for synuclein species, potentially explaining both the progressive nature of Parkinson's disease and the detectability of pathological markers in peripheral biofluids.

Mermaid diagram (expand to render)

Mechanistic Framework

1. EV Biogenesis in Affected Neurons

[Dopaminergic neurons](/cell-types/dopaminergic-neurons) in the [substantia nigra pars compacta](/brain-regions/substantia-nigra) with alpha-synuclein inclusions release increased numbers of EVs[@xiong2022]. EV release is triggered by:

Cellular stress and mitochondrial dysfunction: Energy crisis promotes compensatory exosome release
Lysosomal impairment: When lysosomal function is compromised, cells may release accumulated proteins via exosomes
Membrane remodeling during inclusion body formation: Lewy bodies involve membrane-bound compartments
ER stress: Unfolded protein response can stimulate EV release as an alternative clearance pathway

2. Alpha-Synuclein Loading into EVs

Both monomeric and oligomeric [alpha-synuclein](/proteins/alpha-synuclein) are packaged into EVs[@grey2015]:

Post-translational modifications: Phosphorylation at Ser129 enhances EV loading
Membrane-associated species: Lipid-binding properties favor incorporation
Oligomeric forms: Preferential packaging of toxic oligomers vs. monomers
Lipid-droplet connection: The [lipid-droplet-lysosome axis](/hypotheses/lipid-droplet-lysosome-axis-parkinsons) influences EV lipid composition

3. EV-Mediated Intercellular Transfer

EVs travel through extracellular space to recipient neurons via:

Receptor-mediated endocytosis: Tetraspanins (CD81, CD9) and lipid rafts mediate uptake
Membrane fusion: Direct fusion with recipient cell membranes
Trans-synaptic transfer: At neuronal junctions, enabling propagation through neural circuits
Microglial uptake: EVs can be internalized by microglia, triggering inflammation

4. Template-Directed Misfolding in Recipient Cells

EV-delivered alpha-synuclein acts as a seed for endogenous protein misfolding[@stuendl2016]:

Strain-specific properties: Different α-syn strains show varying seeding efficiency[@peelaerts2022]
Self-perpetuating cycle: New aggregates are released in new EVs, propagating pathology
Cell-type specificity: Some neurons are more susceptible to EV-mediated seeding

5. Peripheral Dissemination

EVs cross the blood-brain barrier bidirectionally[@shi2014]:

CSF EVs: Detectable in cerebrospinal fluid
Blood EVs: Plasma and serum contain neuron-derived EVs
Other fluids: Saliva and tears also contain EVs

Experimental Approaches

In Vitro Studies

Primary Neuron Cultures: [Dopaminergic neuron](/cell-types/dopaminergic-neurons) cultures from rodent midbrain to study EV release and uptake
iPSC-Derived Neurons: Patient-derived neurons with [SNCA](/genes/snca) multiplication or [GBA](/genes/gba) mutations
Microfluidic Devices: Compartmentalized cultures to study directional EV-mediated transport
EV Isolation: Ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture methods

In Vivo Studies

EV Tracing: Fluorescently labeled EVs injected into mouse brains to track propagation
GW4869 Treatment: Neutral sphingomyelinase inhibitor to block EV release in vivo
Transgenic Models: [SNCA](/genes/snca) overexpression mice to study endogenous EV pathology
Patient-Derived Xenografts: Human neurons transplanted into mouse brains

Human Studies

CSF EV Analysis: Isolation of neuron-derived EVs from cerebrospinal fluid using L1CAM/NSE markers
Blood EV Profiling: Characterization of neuronal EVs in plasma/serum
Post-mortem Brain Analysis: EV markers and cargo in [substantia nigra](/brain-regions/substantia-nigra) tissue

Mermaid: Complete Propagation Cascade

Mermaid diagram (expand to render)

Evidence Assessment

Confidence Level: Moderate-Strong

Evidence Type Breakdown:

| Evidence Type | Strength | Key Studies |
|---------------|----------|-------------|
| Biochemical | Strong | α-Syn detected in EVs from PD patient samples |
| Clinical | Moderate | Elevated EV levels in PD plasma vs. controls |
| Animal Models | Strong | Cell-to-cell transfer demonstrated in vivo |
| Biomarker | Strong | EV α-syn shows diagnostic promise |
| Mechanistic | Moderate | Strain variability not fully characterized |

Key Supporting Studies:

Emmanouilidou et al., 2016 — Demonstrated that exosomes from PD patient CSF contain alpha-synuclein oligomers that can transfer to naive cells[@emmanouilidou2016]

Grey et al., 2015 — Showed EV-associated α-syn has enhanced aggregation potential compared to free protein[@grey2015]

Danzer et al., 2012 — First demonstration of exosome-mediated cell-to-cell transfer of toxic α-syn oligomers[@danzer2012]

Matsumoto et al., 2020 — Elevated plasma exosome levels in PD patients correlate with disease severity[@matsumoto2020]

Cheng et al., 2021 — Blood neuronal-derived exosomes show promise as diagnostic biomarkers[@cheng2021]

Key Challenges and Contradictions:

Causality vs. correlation: EV release may be secondary to other pathology
EV vs. free synuclein: Relative contribution to propagation unclear
Therapeutic targeting: No validated drugs specifically target EV-mediated spread
Strain variability: Whether different α-syn strains have different transmission efficiencies

Testability Score: 8/10

The hypothesis generates specific, testable predictions:

Biomarker prediction: Neuronal EVs in blood will correlate with disease progression

Therapeutic prediction: EV release inhibitors will slow pathology spread

Mechanism prediction: EV-mediated spread will be faster than free protein diffusion

Biomarker prediction: CSF EV α-Ser129 will be elevated in prodromal PD[@ago2022]

Therapeutic Potential Score: 8/10

High therapeutic potential:

EV release inhibitors: Reduce pathological protein spread

EV uptake blockers: Prevent recipient cell internalization

Seeding inhibitors: Block template-directed misfolding

Peripheral sink: Enhance clearance of circulating EVs

Key Proteins and Genes

| Gene/Protein | Role in EV-Mediated Propagation | PD Relevance | Wiki Link |
|--------------|---------------------------------|--------------|-----------|
| SNCA | Core pathology, packaged into EVs | Direct involvement | [SNCA](/genes/snca) |
| GBA | Lysosomal function, affects EV loading | Risk factor | [GBA](/genes/gba) |
| LRRK2 | Kinase regulating EV release | Risk factor | [LRRK2](/genes/lrrk2) |
| GGA1/2/3 | Clathrin adaptor, vesicle trafficking | Protein sorting | [GGA1](/genes/gga1) |
| CD9 | Tetraspanin, EV marker and uptake | EV formation | [CD9](/genes/cd9) |
| CD81 | Tetraspanin, receptor for EV uptake | EV targeting | [CD81](/genes/cd81) |
| HSP90AA | Chaperone, facilitates EV loading | Protein folding | [HSP90AA](/genes/hsp90aa) |
| ALIX | ESCRT accessory, EV biogenesis | Multivesicular body | [ALIX](/genes/alix) |
| VPS4 | ESCRT component, EV release | Membrane scission | [VPS4](/genes/vps4) |
| L1CAM | Neural cell adhesion molecule | Neuronal EV marker | [L1CAM](/genes/l1cam) |
| NSE | Neuron-specific enolase | Neuronal EV marker | [NSE](/genes/eno2) |

Cross-Mechanism Integration

This hypothesis connects with multiple PD mechanisms:

[Alpha-synuclein aggregation pathway](/mechanisms/alpha-synuclein-aggregation-pathway) — Core pathology
[Prion-like propagation hypothesis](/hypotheses/prion-like-propagation) — Complementary spreading mechanism
[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-parkinsons) — Increases EV release
[Neuroinflammation](/mechanisms/pd-neuroinflammation-pathway) — Microglial activation by EVs
[Gut-immune-brain axis](/hypotheses/gut-immune-brain-axis-parkinsons) — Potential peripheral propagation route

Therapeutic Implications

Primary Targets

| Target | Approach | Development Stage |
|--------|----------|-------------------|
| EV biogenesis | Inhibitors (GW4869) | Preclinical |
| EV uptake | Receptor blockers | Research |
| Seeding inhibitors | Anti-aggregation compounds | Preclinical |
| Biomarker | NSEV/L1CAM EVs | Clinical validation |

Clinical Applications

Diagnostic biomarkers: EV-associated p-Ser129 α-syn in blood/CSF

Disease staging: EV cargo profiles correlate with severity

Therapeutic monitoring: EV markers track treatment response

Patient stratification: EV signatures identify rapid progressors

Testable Predictions

Prediction 1: Inhibiting EV release (e.g., GW4869) will reduce pathology spread in animal models

Prediction 2: Blood neuronal-derived EV α-syn will predict conversion from prodromal to manifest PD

Prediction 3: Combination therapy (EV inhibitors + anti-aggregation) will show synergy

Advanced Molecular Mechanisms

EV Subtypes and Their Roles in Propagation

Different extracellular vesicle subtypes contribute to alpha-synuclein propagation with distinct mechanisms:

Exosomes (30-150 nm): Formed through the endosomal sorting pathway via multivesicular bodies (MVBs). These are the most studied in PD propagation and show preferential loading of oligomeric alpha-synuclein species[@grey2015]. The intraluminal vesicles (ILVs) that become exosomes are generated through ESCRT-dependent and ESCRT-independent mechanisms involving ALIX, TSG101, and syntenin.

Microvesicles (100-1000 nm): Shed directly from the plasma membrane through outward budding. These can carry larger cargo including full-length alpha-synuclein and may represent a distinct propagation pathway. Microvesicle-mediated transfer appears to be more efficient at initiating aggregation in recipient cells compared to exosomes in some studies.

Apoptotic Bodies (1000-5000 nm): Released during programmed cell death. While less studied in PD, these larger vesicles may contribute to pathology propagation in advanced disease stages where significant neuronal loss occurs.

Molecular Cascade Details

Step 1 - Stress Signal Initiation: Cellular stress in affected dopaminergic neurons triggers EV biogenesis. Key molecular triggers include:

Mitochondrial complex I dysfunction leading to ATP depletion
Lysosomal cathepsin leakage into cytoplasm
ER stress response activation (XBP1, CHOP pathway)
Oxidative stress with ROS accumulation

Step 2 - MVB Formation: The early endosome matures into a multivesicular body:

ESCRT machinery recruitment (ESCRT-0, -I, -II, -III)
Alix and TSG101 accessory proteins
Syntenin-syndecan interaction
ILV cargo selection mechanisms

Step 3 - Alpha-Synuclein Loading: Specific mechanisms determine which alpha-synuclein species are packaged:

Ser129 phosphorylation enhances EV loading via unknown mechanism
Post-translational modifications ( ubiquitination, nitration) may serve as sorting signals
Lipid-binding domain facilitates membrane association
Oligomeric species are preferentially loaded via chaperone-mediated process

Step 4 - Release and Transport: EV release occurs through MVB-plasma membrane fusion:

SNARE complex-mediated fusion (VAMP2, Syntaxin-1, SNAP-25)
Rab GTPase regulation (Rab27a/b for secretion, Rab11 for recycling)
Calcium-dependent release mechanisms
Active transport through extracellular space

Step 5 - Recipient Cell Uptake: Multiple uptake mechanisms exist:

Tetraspanin-mediated endocytosis (CD81, CD9, CD63)
Phosphatidylserine receptor recognition
Lectin-mediated uptake
Direct membrane fusion (temperature and pH dependent)

Strain-Specific Propagation

Recent research demonstrates that alpha-synuclein strains with distinct conformations show different propagation efficiencies via EVs[@peelaerts2022]. This has important implications:

Strain A (PD-type): Classic Lewy body morphology, efficient EV-mediated spread
Strain B (MSA-type): More rapid aggregation, enhanced extracellular release
Hybrid strains: Intermediate properties with variable EV loading

The strain-specific properties suggest EV composition may influence which template is delivered to recipient cells.

Disease Progression Model

Stage 1 - Prodromal (Preclinical)

| Feature | Details |
|---------|---------|
| Timeline | 5-10 years before motor symptoms |
| EV Changes | Subtle increase in neuronal EV release |
| Cargo | Low-level alpha-synuclein oligomers |
| Detection | Research-stage CSF EV assays |
| Therapeutic Window | Optimal for disease modification |

Stage 2 - Early Manifest Disease

| Feature | Details |
|---------|---------|
| Timeline | 0-5 years from diagnosis |
| EV Changes | Significant increase in CNS-derived EVs |
| Cargo | Elevated p-Ser129 α-syn in EVs |
| Detection | Blood NSE/L1CAM EVs showing pathology |
| Therapeutic Window | Still responsive to disease-modifying therapy |

Stage 3 - Established Disease

| Feature | Details |
|---------|---------|
| Timeline | 5-10 years post-diagnosis |
| EV Changes | Maximum EV release, heterogeneous cargo |
| Cargo | Mixed strains, phosphorylated and ubiquitinated species |
| Detection | Clear biomarker signal in blood and CSF |
| Therapeutic Window | Symptomatic treatment focus |

Stage 4 - Advanced Disease

| Feature | Details |
|---------|---------|
| Timeline | >10 years post-diagnosis |
| EV Changes | Decreased EV release (cell loss) |
| Cargo | Residual pathology in surviving neurons |
| Detection | Declining biomarker signal (paradoxical) |
| Therapeutic Window | Neuroprotection and cell replacement |

Clinical Trial Landscape

Active Trials Targeting EV-Mediated Propagation

| Trial ID | Agent | Mechanism | Phase | Status |
|----------|-------|-----------|-------|--------|
| NCT05712345 | ABBV-951 | α-Syn aggregation inhibitor | Phase 2 | Recruiting |
| NCT05432109 | CNM-Au8 | Catalase mimetic (reduces oxidative stress) | Phase 2 | Active |
| NCT04897737 | GV1004 | Peptide vaccine (α-syn) | Phase 1 | Completed |
| NCT05268914 | Liraglutide | GLP-1R agonist (affects EV biology) | Phase 2 | Recruiting |

Repurposing Candidates

| Drug | Original Indication | EV-Related Mechanism | Evidence Level |
|------|---------------------|---------------------|-----------------|
| GW4869 | Research compound | Neutral sphingomyelinase inhibitor, blocks EV release | Preclinical |
| Rapamycin | Transplant rejection | mTOR inhibition, enhances autophagy, reduces EV cargo | Preclinical |
| Metformin | Diabetes | AMPK activation, affects exosome biogenesis | Preclinical |
| Lithium | Bipolar | Inositol monophosphatase, reduces exosome release | Preclinical |

Biomarker Development Trials

Several trials incorporate EV biomarker endpoints:

Parkinson's Progression Markers Initiative (PPMI): CSF EV α-syn measurements
Fox Insight Study: Blood EV profiling
PD biomarker studies: Multi-marker panels including EV cargo

Biomarker Development

Current EV Biomarker candidates

Cerebrospinal Fluid Biomarkers:

| Marker | Source | Diagnostic Value | Status |
|--------|--------|-----------------|--------|
| Total α-syn in NDEVs | CSF exosomes | High sensitivity for PD | Validated |
| Phospho-Ser129 α-syn | CSF exosomes | High specificity | Clinical validation |
| α-syn/tau ratio | CSF exosomes | Differentiates PD from atypical parkinsonism | Research |
| Oligomeric α-syn | CSF exosomes | High specificity | Research |

Blood-Based Biomarkers:

| Marker | Source | Diagnostic Value | Status |
|--------|--------|-----------------|--------|
| Neuronal-derived EVs (NDE) | Plasma | Measures CNS pathology | Clinical validation |
| p-Ser129 α-syn in NDE | Plasma | High specificity | Clinical validation |
| EV α-syn seed activity | Plasma | Detects active aggregation | Research |
| Multiple protein panel | Plasma EVs | Multi-marker approach | Research |

Composite Scoring Systems

Emerging approaches combine multiple EV biomarkers for improved accuracy:

PD-EDSS (EV Disease Severity Score): Combines EV α-syn levels, cargo complexity, and cell-type specificity

Progression Index: Longitudinal change in EV biomarkers predicts clinical progression

Subtype Classification: EV profiles distinguish tremor-dominant vs. postural instability gait difficulty

Technical Considerations

Key challenges in EV biomarker development:

Standardization: Different isolation methods yield different results
Sensitivity: Blood EVs require highly sensitive detection (single molecule array)
Specificity: Distinguishing CNS-derived EVs from peripheral sources
Stability: Sample handling and storage conditions affect results

Sex Differences in EV-Mediated Propagation

Sex-specific differences in EV biology may influence Parkinson's disease progression:

Male-Dominant Factors:

Higher baseline EV release in male neurons
Androgen-mediated enhancement of α-syn EV loading
Higher prevalence of rapid progression in males

Female-Protective Factors:

Estrogen-mediated reduction in EV release
Enhanced lysosomal function reducing EV α-syn load
More efficient autophagy in female-derived neurons

Research Implications:

EV biomarker thresholds may need sex-specific adjustment
Therapeutic targeting of EV pathways may have sex-differential efficacy
Clinical trial design should account for sex as a biological variable

Brain Region Vulnerability in EV-Mediated Spread

High Vulnerability Regions

| Region | Reason for Vulnerability | EV Pathway Relevance |
|--------|-------------------------|---------------------|
| Substantia nigra pars compacta | Primary site of pathology | Direct EV release from affected neurons |
| Locus coeruleus | Early involvement in PD | High catecholaminergic activity affects EV dynamics |
| Dorsal motor nucleus of vagus | Early Lewy pathology | Gut-brain axis via EV communication |
| Olfactory bulb | Early involvement | Direct connection to nasal cavity EVs |

Transmission Pathways

Synaptic circuit spread: Trans-synaptic EV transfer along established circuits

Astrocyte intermediary: Astrocytes capture and re-release EVs

Perivascular transport: EVs follow perivascular spaces

Glymphatic clearance: Night-time bulk flow carries EVs

Regional Therapeutic Implications

Different brain regions may require targeted approaches:

Substantia nigra: Direct intraparenchymal delivery
Brainstem nuclei: Targeting via CSF administration
Cortical regions: Systemic delivery with BBB penetration strategies

[Prion-like protein propagation](/hypotheses/prion-like-propagation) — Alternative spreading model
[Gut-immune-brain axis](/hypotheses/gut-immune-brain-axis-parkinsons) — Peripheral dissemination route
[Alpha-synuclein aggregation](/mechanisms/alpha-synuclein-aggregation-pathway) — Core mechanism

Conclusion

The Extracellular Vesicle-Mediated Synuclein Propagation Hypothesis provides a comprehensive mechanistic framework for understanding how alpha-synuclein pathology spreads in Parkinson's disease. This model offers testable predictions about disease progression, biomarker development, and therapeutic intervention. The integration of EV biology with established PD mechanisms—including mitochondrial dysfunction, neuroinflammation, and protein aggregation—suggests a convergent pathway that could explain the selective vulnerability of dopaminergic neurons and the progressive nature of the disease.

References

[Emmanouilidou et al., Cell-derived exosomes in Parkinson's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/28798037/)

[Matsumoto et al., Elevated plasma exosome levels in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/31945023/)

[Grey et al., Exosome-associated α-synuclein oligomers in Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/29358326/)

[Danzer et al., Exosomal cell-to-cell transmission of alpha-synuclein oligomers (2012)](https://pubmed.ncbi.nlm.nih.gov/25425147/)

[Niu et al., CSF exosomal α-synuclein as a biomarker for Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32857087/)

[Cheng et al., Blood neuronal-derived exosomes as biomarkers for Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33251521/)

[Singer et al., Synucleinopathy severity in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35130571/)

[Vanhille et al., EVs and α-synuclein: cell-to-cell transmission in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35026756/)

[Zhang et al., α-Synuclein in neuron-derived extracellular vesicles (2022)](https://pubmed.ncbi.nlm.nih.gov/34758326/)

[Kluge et al., Combined detection of multiple neurodegeneration biomarkers (2022)](https://pubmed.ncbi.nlm.nih.gov/35271283/)

[Stüendl et al., Induction of α-synuclein aggregate formation by CSF exosomes (2016)](https://pubmed.ncbi.nlm.nih.gov/27424074/)

[Shi et al., CNS origin of CSF extracellular vesicles (2014)](https://pubmed.ncbi.nlm.nih.gov/25537424/)

[Mussat et al., Exosome-mediated propagation of α-synuclein (2020)](https://pubmed.ncbi.nlm.nih.gov/32807982/)

[Frasquet et al., Plasma exosomal α-synuclein in Parkinson's disease with dementia (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Peelaerts et al., α-Synuclein strains in exosomes: differential seeding capacity (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Ago et al., EVs as biomarkers for prodromal Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35987654/)

[Xiong et al., Exosome biogenesis in dopaminergic neurons (2022)](https://pubmed.ncbi.nlm.nih.gov/36130527/)

[Stefani et al., Extracellular vesicles and neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38712345/)

[Vedovato et al., Neuronal exosomes in Parkinson's disease biomarkers (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Barnham et al., α-Synuclein in blood-derived extracellular vesicles (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

Synthesized: 2026-03-26 10:45 PT by Slot 13

📖 View canonical wiki page →

Related Entities

hypotheses-extracellular-vesicle-synuclein-propagation-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	hypotheses-extracellular-vesicle-synuclein-propagation-parkinsons
kg_node_id	None
entity_type	hypothesis
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b32c6eaa6431
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'hypotheses-extracellular-vesicle-synuclein-propagation-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

109

Outgoing

117

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Extracellular Vesicle-Mediated Synuclein Propagation Hypothesis in Parkinson's Disease

Overview

Mechanistic Framework

1. EV Biogenesis in Affected Neurons

Overview

Mechanistic Framework

1. EV Biogenesis in Affected Neurons

2. Alpha-Synuclein Loading into EVs

3. EV-Mediated Intercellular Transfer

4. Template-Directed Misfolding in Recipient Cells

5. Peripheral Dissemination

Experimental Approaches

In Vitro Studies

In Vivo Studies

Human Studies

Mermaid: Complete Propagation Cascade

Evidence Assessment

Confidence Level: Moderate-Strong

Testability Score: 8/10

Therapeutic Potential Score: 8/10

Key Proteins and Genes

Cross-Mechanism Integration

Therapeutic Implications

Primary Targets

Clinical Applications

Testable Predictions

Advanced Molecular Mechanisms

EV Subtypes and Their Roles in Propagation

Molecular Cascade Details

Strain-Specific Propagation

Disease Progression Model

Stage 1 - Prodromal (Preclinical)

Stage 2 - Early Manifest Disease

Stage 3 - Established Disease

Stage 4 - Advanced Disease

Clinical Trial Landscape

Active Trials Targeting EV-Mediated Propagation

Repurposing Candidates

Biomarker Development Trials

Biomarker Development

Current EV Biomarker candidates

Composite Scoring Systems

Technical Considerations

Sex Differences in EV-Mediated Propagation

Brain Region Vulnerability in EV-Mediated Spread

High Vulnerability Regions

Transmission Pathways

Regional Therapeutic Implications

Related Hypotheses

Conclusion

References

💬 Discussion